Rallybio (RLYB) Stock Price, News & Analysis

Company Overview

Rallybio Therapeutics, Inc. (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency. Additional pipeline candidates target lysosomal storage disorders and severe skin fragility syndromes, underscoring the company’s commitment to a precision‐medicine approach. Each program has been selected based on compelling preclinical or early clinical data that suggest a clear path to regulatory milestones and commercialization.

Founded in 2018 and headquartered in New York City, Rallybio completed its initial public offering via a business combination in 2021. The company leverages strategic partnerships, external research collaborations and internal manufacturing capabilities to accelerate development timelines and maintain rigorous quality standards. While Rallybio’s primary operations are based in the United States, its clinical trial network spans North America, Europe and Asia Pacific, reflecting its objective to serve rare disease communities on a global scale.

Rallybio is led by a management team with extensive experience in rare disease research, drug development and regulatory strategy. The company aims to build on its scientific foundation by expanding its pipeline, advancing key assets toward commercialization and fostering collaborations that enhance access to therapies for underserved patient populations worldwide.

Key Stats

• Today's Range: $0.53 to $0.55
• 50-Day Range: $0.50 to $0.63
• 52-Week Range: $0.22 to $1.24
• Volume: 102,556 shs
• Average Volume: 342,998 shs
• Market Capitalization: $22.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Reduce

Rallybio Stock Analysis - MarketRank™

Rallybio scored higher than 56% of companies evaluated by MarketBeat, and ranked 466th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Rallybio has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Rallybio has a consensus price target of $5.00, representing about 834.4% upside from its current price of $0.54.

Amount of Analyst Coverage

Rallybio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rallybio are expected to grow in the coming year, from ($1.34) to ($1.09) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rallybio is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rallybio is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rallybio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.61% of the float of Rallybio has been sold short.

Short Interest Ratio / Days to Cover

Rallybio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rallybio has recently decreased by 21.48%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rallybio does not currently pay a dividend.

Dividend Growth

Rallybio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.61% of the float of Rallybio has been sold short.

Short Interest Ratio / Days to Cover

Rallybio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rallybio has recently decreased by 21.48%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: N/A

News Sentiment

Rallybio has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.

Search Interest

Only 1 people have searched for RLYB on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

4 people have added Rallybio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rallybio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.70% of the stock of Rallybio is held by insiders.

Percentage Held by Institutions

90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RLYB Stock Analysis - Frequently Asked Questions

How have RLYB shares performed this year?

Rallybio's stock was trading at $0.96 at the start of the year. Since then, RLYB shares have decreased by 44.3% and is now trading at $0.5351.

How were Rallybio's earnings last quarter?

Rallybio Corporation (NASDAQ:RLYB) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. The business had revenue of $0.21 million for the quarter. Rallybio had a negative net margin of 5,473.33% and a negative trailing twelve-month return on equity of 71.66%.

When did Rallybio IPO?

Rallybio (RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share.

How do I buy shares of Rallybio?

Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rallybio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/19/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RLYB
• CIK: 1739410
• Web: www.rallybio.com
• Phone: 203-59-3820
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Rallybio: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +834.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.78 million
• Net Margins: -5,473.33%
• Pretax Margin: -5,218.27%
• Return on Equity: -71.66%
• Return on Assets: -65.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.98
• Quick Ratio: 9.98

Sales & Book Value

• Annual Sales: $640 thousand
• Price / Sales: 34.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.49 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 41,790,000
• Free Float: 38,151,000
• Market Cap: $22.36 million
• Optionable: Not Optionable
• Beta: -1.10